Chemomab Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Chemomab Therapeutics has a total shareholder equity of $13.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $18.0M and $4.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$15.88m |
Equity | US$13.33m |
Total liabilities | US$4.68m |
Total assets | US$18.01m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2QV0's short term assets ($16.8M) exceed its short term liabilities ($4.4M).
Long Term Liabilities: 2QV0's short term assets ($16.8M) exceed its long term liabilities ($280.0K).
Debt to Equity History and Analysis
Debt Level: 2QV0 is debt free.
Reducing Debt: 2QV0 has no debt compared to 5 years ago when its debt to equity ratio was 0.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2QV0 has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 2QV0 is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.